+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The relationship between myasthenia gravis and the different pathological type of thymoma patients' operation and prognosis

The relationship between myasthenia gravis and the different pathological type of thymoma patients' operation and prognosis

Zhonghua Wai Ke Za Zhi 53(8): 612-616

To evaluate the different pathological and clinical characteristics of thymomas with and without myasthenia gravis (MG) and to determine whether the presence of MG influences the prognosis in thymoma patients. The clinical data from 228 consecutive patients (median sternotomy were used in 153, video-assisted thoracoscopic themectomy were used in 75) operated on from January 1992 to December 2007 was analyzed retrospectively. These thymoma patients had been subdivided into two groups: thymoma with MG (n = 125) and thymoma without MG (n = 103). All thymic epithelial tumors were classified according to the WHO histologic classification and the Masaoka clinical staging system. The result was evaluated according to the Myasthenia Gravis Foundation of America's criterion. The clinical features of the 2 test was compared between the two groups by χ² test, and the survival were compared between the two groups by Cox analysis. There were no peri-operative deaths. 19 cases were inoperable (6 in the group with MG, 13 without MG (χ² = 4.52, P = 0.035)). The proportions of type A and thymic carcinoma were 0 in the group with MG, 10.5% (11/103) and 11.6% (12/103) respectively in the group without MG. According to the Masaoka's clinical staging, in the group MG, 24.8% (31/125) patients were stage III and IV; in the group without MG, 33.0% (34/103) patients were stage III and IV. There was a significant difference between hyperplastic paraneoplastic thymus coexisting in 28.8% (36/125) patients with MG and only 5.8% (6/103) in patients without MG (χ² = 20.91, P = 0.000) Microthymoma was identified in the paraneoplastic thymus of 3 patients with MG. There were 198 patients followed up, the rate was 86.8% (198/228). There was no recurrence in patients with type A and a few patients with type AB, B1, B2, B3 thymoma and thymic carcinoma recurred. The actuarial 5- and 10-year survival rates were 89.3% and 81.2% for patients with MG respectively, and 90.0% and 78.9% for patients without MG respectively. Within 5 years postoperatively, 6 of 9 patients with MG died of myasthenia crisis, while 6 out of 7 deaths in patients without MG were attributable to inoperable tumors (stage IV) and thymic carcinoma. The existence of myasthenia gravis has little influence on the prognosis of thymomas, but it is good for early diagnosis and treatment. Extended thymectomy should be performed to all patients with thymoma, no matter they have myasthenia gravis or not. The main cause of death is myasthenia crisis for thymoma patients with MG and stage IV and (or) thymic carcinoma for patients without MG.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 059099276

Download citation: RISBibTeXText

PMID: 26653963

Related references

Myasthenia gravis with thymoma: analysis of and postoperative prognosis for 65 patients with thymomatous myasthenia gravis. Annals of Thoracic Surgery 38(1): 46-52, 1984

Clinical Study on the Prognosis of Patients with Thymoma with Myasthenia Gravis. Zhongguo Fei Ai Za Zhi 21(1): 1-7, 2018

Pathological Findings in Myasthenia Gravis Patients with Thymic Hyperplasia and Thymoma. Pathology Oncology Research 24(1): 67-74, 2018

Myasthenia gravis: a clinical and pathological study of a case associated with a primary mediastinal thymoma and a solitary secondary intrapulmonary thymoma. New England Journal of Medicine 243(13): 478-482, 1950

Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis. Journal of Neuroimmunology 258(1-2): 61-66, 2013

Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. Journal of Neuroimmunology 201-202: 237-244, 2008

Pemphigus foliaceus, myasthenia gravis, thymoma and red cell aplasia. A case report and indirect immunofluorescence study on 38 patients with myasthenia gravis. Clinical and Experimental Dermatology 3(3): 285-291, 1978

Using histochemical methods to study pathological features of hyperplastic thymus and thymoma in patients with myasthenia gravis. Annals of the new York Academy of Sciences 841: 427-429, 1998

Relationship between expression of Cat V and clinicopathologic character of myasthenia gravis in patients with thymoma. Sichuan Da Xue Xue Bao. Yi Xue Ban 37(6): 886-888, 2006

Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations. Tissue Antigens 37(2): 90-93, 1991

Prognosis of thymoma with myasthenia gravis. Rinsho Hoshasen. Clinical Radiography 32(10): 1119-1123, 1987

Surgical treatment in the patients with ocular type myasthenia gravis associated with thymoma. Nihon Kyobu Geka Gakkai 41(7): 1204-1207, 1993

The pathological basis of thymoma-associated myasthenia gravis. Annals of the new York Academy of Sciences 681: 56-65, 1993

Anti-skeletal muscle and anti-acetylcholine receptor antibodies in patients with thymoma without myasthenia gravis: relation to the onset of myasthenia gravis. Clinica Chimica Acta; International Journal of Clinical Chemistry 201(3): 201-205, 1991

Thymoma and myasthenia gravis: clinical aspects and prognosis. Asian Cardiovascular and Thoracic Annals 20(1): 48-52, 2012